Discussion on the efficacy of trametinib

Trametinib, available as monotherapy or in combination with dabrafenib (trade name: Tafinlar), is designed to treat a specific type of melanoma, a type of skin cancer. In addition, it also plays a role in preventing the recurrence of certain melanomas after surgery in combination with dabrafenib. This combination therapy is also widely used to treat certain types of non-small cell lung cancer (NSCLC), thyroid cancer, and certain solid tumors in adults and children older than 6 years of age. In children 1 year and older, this therapy is also used to treat a certain type of glioma.

The U.S. Food and Drug Administration (FDA) approved trametinib based on an international multicenter, randomized, open-label, active-controlled trial involving 322 patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma. These patients all had advanced or metastatic disease and had not previously received more than one chemotherapy regimen, nor had they been treated with BRAF inhibitors or MEK inhibitors. The subjects were randomly divided into two groups, one group received oral trametinib 2 mg daily (N=214), and the other group received chemotherapy (N=108). The chemotherapy regimen included intravenous injection of dacarbazine 1,000 mg/m2 or paclitaxel 175 mg/m2 every 3 weeks. Treatment was continued until disease progression or unacceptable toxicity. The primary outcome measure of the study is progression-free survival (PFS).

The study results showed that in the trametinib group,50% of patients had disease progression, while 65% of patients in the chemotherapy group had disease progression. The median time to disease progression in the two groups was 4.8 months and 1.5 months, respectively.

However, it is important to note that the efficacy of trametinib will vary from individual to individual, and for optimal therapeutic effect, the drug often needs to be used in combination with other drugs. Therefore, before starting trametinib treatment, patients should consult a professional physician and strictly follow the medical instructions for treatment.